{"denoms":[{"counts":[{"groupId":"BG000","value":"410"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"616"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\\^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)","id":"BG000","title":"Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed"},{"description":"Participants received saline placebo IV PLUS pemetrexed 500 mg/m\\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m\\^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)","id":"BG001","title":"Control"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.4","value":"63.2"},{"groupId":"BG001","spread":"9.1","value":"62.8"},{"groupId":"BG002","spread":"9.3","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"253"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"363"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"387"},{"groupId":"BG001","value":"195"},{"groupId":"BG002","value":"582"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"190"}]}],"title":"TPS <1%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"388"}]}],"title":"TPS ≥1%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"38"}]}],"title":"Not Evaluable"}],"description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS \\<1% were classified as PD-L1 negative.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"171"}]}],"title":"Cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"445"}]}],"title":"Carboplatin"}],"description":"Participants were classified according to the type of platinum chemotherapy the Investigator chose for them to receive: Cisplatin or Carboplatin.","paramType":"COUNT_OF_PARTICIPANTS","title":"Platinum Chemotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"73"}]}],"title":"Never Smoker"},{"categories":[{"measurements":[{"groupId":"BG000","value":"362"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"543"}]}],"title":"Former/Current Smoker"}],"description":"Participants were classified according to their smoking status: Never Smoker or Former/Current Smoker.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking Status","unitOfMeasure":"Participants"}],"populationDescription":"The Baseline Analysis Population consisted of all randomized participants."}